AIM ImmunoTech Inc. vs. Amgen Inc
AIM ImmunoTech Inc. (AIM) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AIM | AMGN | |
|---|---|---|
| Market Cap | $6.69 million | $224.63 billion |
| Revenue (TTM) | — | $38.09 billion |
| Net Income (TTM) | — | $8.74 billion |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AIM | AMGN | |
|---|---|---|
| P/E Ratio | — | 26.05 |
| Price / Book | 0.57 | 19.22 |
| Price / Sales | — | 5.90 |
AIM leads on 1 of 1 valuation factors.
Profitability
| AIM | AMGN | |
|---|---|---|
| Net Margin | — | 22.95% |
| Return on Equity | — | 74.80% |
AIM and AMGN split the profitability factors evenly.
Dividend
| AIM | AMGN | |
|---|---|---|
| Dividend Yield | — | 2.40% |
| Payout Ratio | — | 62.61 |
AIM and AMGN split the dividend factors evenly.
Risk & Sentiment
| AIM | AMGN | |
|---|---|---|
| Short Interest | 0.32% | 1.66% |
AIM leads on 1 of 1 risk & sentiment factors.
Dig deeper: AIM overview, AIM financials, AMGN overview, AMGN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.